Raymond James Initiates Coverage On Tonix Pharmaceuticals with Strong Buy Rating, Announces Price Target of $26
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsInitiationPrice Target
Raymond James analyst Tiago Fauth initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Strong Buy rating and announces Price Target of $26.
Raymond James analyst Tiago Fauth initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Strong Buy rating and announces Price Target of $26.